Regenxbio Inc (RGNX)

Mar 26, 2025, 12:31 PM EDT - 8 days ago

5 Reasons To Buy Regenxbio Right Now

Mar 19, 2025, 9:15 AM EDT - 15 days ago

REGENXBIO REPORTS POSITIVE BIOMARKER DATA FROM AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY

Mar 13, 2025, 6:44 PM EDT - 21 days ago

REGENXBIO Inc. (RGNX) Q4 2024 Earnings Call Transcript

Mar 13, 2025, 4:05 PM EDT - 21 days ago

REGENXBIO Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Updates

Mar 10, 2025, 7:05 AM EDT - 24 days ago

REGENXBIO Announces Presentations at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Mar 4, 2025, 7:31 AM EST - 4 weeks ago

REGENXBIO Announces Closing of Strategic Partnership with Nippon Shinyaku for MPS Diseases

Feb 26, 2025, 4:05 PM EST - 5 weeks ago

REGENXBIO to Host Conference Call on March 13 to Discuss Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Highlights

Feb 25, 2025, 4:05 PM EST - 5 weeks ago

REGENXBIO to Participate in Upcoming Investor Conferences

Feb 11, 2025, 3:20 PM EST - 7 weeks ago

Regenxbio's Gene Therapy Outlook Dims As Rival Treatments Gain Ground, Goldman Sachs Warns

Jan 30, 2025, 7:05 AM EST - 2 months ago

REGENXBIO Announces Presentations of RGX-121 at the 21st Annual WORLDSymposium 2025

Jan 16, 2025, 4:01 AM EST - 2 months ago

Regenxbio: Wet AMD ABBV-RGX-314 Results Remain On Track For 2026

AMD

Jan 15, 2025, 3:27 PM EST - 2 months ago

Regenxbio Inc.: Why It Is Down, And When It Will Go Up Again

Jan 14, 2025, 5:00 AM EST - 2 months ago

REGENXBIO and Nippon Shinyaku Announce Exclusive Partnership to Develop and Commercialize RGX-121 and RGX-111 for MPS Diseases

Jan 13, 2025, 8:31 AM EST - 2 months ago

AbbVie and REGENXBIO Announce Updates on the ABBV-RGX-314 Clinical Program

ABBV

Dec 6, 2024, 6:29 PM EST - 4 months ago

Apollo Global Management and Workday Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

AMTM APO CMA CRI CRS HPP KELYA

Nov 18, 2024, 7:05 AM EST - 4 months ago

REGENXBIO INITIATES PIVOTAL PHASE OF AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY AND REPORTS POSITIVE FUNCTIONAL DATA

Nov 14, 2024, 7:05 AM EST - 5 months ago

REGENXBIO to Host Webcast Discussing Pivotal Program and First Functional Data from the AFFINITY DUCHENNE® Trial of RGX-202

Nov 6, 2024, 11:16 PM EST - 5 months ago

REGENXBIO Inc. (RGNX) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 4:05 PM EST - 5 months ago

REGENXBIO Reports Third Quarter 2024 Financial Results and Recent Operational Updates

Oct 31, 2024, 3:38 PM EDT - 5 months ago

REGENXBIO: With Additional MPS II Data, Program Advancement Remains On Track

Oct 30, 2024, 7:05 AM EDT - 5 months ago

REGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2024 Financial Results and Recent Operational Highlights

Oct 21, 2024, 7:05 AM EDT - 5 months ago

REGENXBIO Presents Positive Data from the Phase II Study of Subretinal ABBV-RGX-314 in Patients with Bilateral Wet AMD at AAO 2024

Oct 18, 2024, 7:05 AM EDT - 5 months ago

REGENXBIO Announces Presentations at the American Academy of Ophthalmology 2024 Annual Meeting

Sep 23, 2024, 4:05 PM EDT - 6 months ago

REGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines Conference

Sep 17, 2024, 7:05 AM EDT - 7 months ago

REGENXBIO Appoints Mitchell Chan as Chief Financial Officer

Sep 3, 2024, 8:04 AM EDT - 7 months ago

REGENXBIO Announces Positive Data from Pivotal Dose Level of RGX-121 Demonstrating Long-Term Systemic Effect

Aug 27, 2024, 7:05 AM EDT - 7 months ago

REGENXBIO Announces Presentation at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual Symposium

Aug 8, 2024, 7:05 AM EDT - 8 months ago

REGENXBIO to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Aug 6, 2024, 4:03 PM EDT - 8 months ago

Regenxbio: RGX-121 Could Achieve A First For Rare Neurodegenerative Disorder

Aug 1, 2024, 11:06 PM EDT - 8 months ago

REGENXBIO Inc. (RGNX) Q2 2024 Earnings Call Transcript

Aug 1, 2024, 4:05 PM EDT - 8 months ago

REGENXBIO Reports Second Quarter 2024 Financial Results and Recent Operational Highlights

Aug 1, 2024, 7:03 AM EDT - 8 months ago

REGENXBIO ANNOUNCES NEW POSITIVE DATA FROM AFFINITY DUCHENNE® TRIAL OF RGX-202

Jul 25, 2024, 7:05 AM EDT - 9 months ago

REGENXBIO to Host Conference Call on August 1 to Discuss Second Quarter 2024 Financial Results and Recent Operational Highlights

Jun 24, 2024, 7:05 AM EDT - 10 months ago

REGENXBIO Announces Expansion of AFFINITY DUCHENNE® Trial to Include a New Cohort of Younger Patients

Jun 18, 2024, 7:05 AM EDT - 10 months ago

REGENXBIO Announces Successful Pre-BLA Meeting with FDA to Support Accelerated Approval Pathway for RGX-121 for the Treatment of MPS II

Jun 12, 2024, 7:05 AM EDT - 10 months ago

REGENXBIO Announces Leadership Transition

Jun 10, 2024, 11:55 PM EDT - 10 months ago

Regenxbio: Transforming Gene Therapy With Innovative AAV Treatments, Strong Buy

Jun 5, 2024, 7:05 AM EDT - 10 months ago

REGENXBIO to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

May 8, 2024, 9:42 PM EDT - 11 months ago

REGENXBIO Inc. (RGNX) Q1 2024 Earnings Call Transcript

May 8, 2024, 4:05 PM EDT - 11 months ago

REGENXBIO Reports First Quarter 2024 Financial Results and Recent Operational Highlights

May 1, 2024, 7:05 AM EDT - 1 year ago

REGENXBIO to Host Conference Call on May 8 to Discuss First Quarter 2024 Financial Results and Recent Operational Highlights

Apr 24, 2024, 7:05 AM EDT - 1 year ago

REGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

Mar 28, 2024, 7:05 AM EDT - 1 year ago

REGENXBIO Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMD

Mar 27, 2024, 4:05 PM EDT - 1 year ago

REGENXBIO to Participate in Cantor Fitzgerald's Virtual DMD and Other Dystrophy Days

Mar 11, 2024, 11:53 AM EDT - 1 year ago

Regenxbio: DMD Program Lends Additional Credibility To NAV Technology Platform

Mar 6, 2024, 11:20 PM EST - 1 year ago

REGENXBIO Announces Pricing of Upsized Public Offering of Common Stock and Pre-funded Warrants

Mar 6, 2024, 4:10 PM EST - 1 year ago

REGENXBIO Announces Proposed Public Offering of Common Stock

Mar 5, 2024, 7:05 AM EST - 1 year ago

REGENXBIO ANNOUNCES NEW POSITIVE INITIAL EFFICACY DATA FROM AFFINITY DUCHENNE® TRIAL

Feb 29, 2024, 4:57 PM EST - 1 year ago

REGENXBIO to Host Webcast Event to Discuss New Interim Clinical Data from the Phase I/II AFFINITY DUCHENNE® Trial

Feb 27, 2024, 9:45 PM EST - 1 year ago

REGENXBIO Inc. (RGNX) Q4 2023 Earnings Call Transcript